Corbus Pharmaceuticals Holdings Inc Stock News

NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript

Positive drug trial results are boosting pharmaceutical stocks today, with Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) and Eli Lilly & Co. (NYSE:LLY) drawing investor attention after encouraging developments for their latest obesity drugs.

NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study ("CANYON-1"), with completion expected in summer 202...

Company will host conference call and live webcast to review and discuss the data at 8:00 am ET Company will host conference call and live webcast to review and discuss the data at 8:00 am ET

NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced it will be participating in the following investor conferences.

Corbus Pharmaceuticals is continuing to march forward with their Nectin-4 ADC, with recent data showcasing impressive tolerability in particular. A recent fundraising for around $75 million was a strong negative catalyst, but it puts their runway right for now. Strong upside potential is here, but there are serious risks in jumping in to an early-phase company.

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchas...